Homepage > Company > Media > Pharma News > 2022 > NICE Recommends Biogen’s Multiple Sclerosis Drug Vumerity

NICE Recommends Biogen’s Multiple Sclerosis Drug Vumerity

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Biogen’s Vumerity (diroximel fumarate) for National Health Service (NHS) use for the treatment of relapsing-remitting multiple sclerosis.

NICE said Vumerity is likely to be as effective as dimethyl fumarate, but with the added benefit of causing fewer gastrointestinal side effects.

The UK list price of Vumerity is $1,900 per pack, which consists of 120 capsules containing 231 mg each. The discounted price for NHS coverage was not disclosed.

April 14, 2022

https://www.fdanews.com/

Read also

AskBio’s AB-1002 gene therapy receives FDA Fast-Track status

The US Food and Drug Administration (FDA) has granted fast-track designation to Bayer subsidiary Asklepios BioPharmaceutical’s (AskBio) investigational gene therapy AB-1002, aimed at...

“Lack of harmonisation in Europe” hindering gene therapy growth

The future of cell and gene therapy access in Europe could be more precarious than across the pond.

Moderna stock on track for the eighth consecutive day of losses

Moderna shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost about 29.6% in the last 12 months and YTD, the st...

Alvotech moves to bring its Humira biosimilar to US market

Hot on the heels of a US Food and Drug Administration (FDA) approval for Alvotech and Teva Pharmaceuticals’ Simlandi (adalimumab-ryvk), Alvotech has announced a long-term agreement w...